# Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer

> **NCT00438100** · PHASE2 · COMPLETED · sponsor: **Japan Breast Cancer Research Network** · enrollment: 142 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** S-1

## Key facts

- **NCT ID:** NCT00438100
- **Lead sponsor:** Japan Breast Cancer Research Network
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2012-07
- **Final completion:** 2013-05
- **Target enrollment:** 142 (ACTUAL)
- **Last updated:** 2015-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00438100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00438100, "Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00438100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*